Gubra (GUBRA) Hisse Özeti
Bir biyoteknoloji şirketi olan Gubra A/S, Avrupa, Kuzey Amerika ve uluslararası alanda metabolik ve fibrotik hastalıklarda klinik öncesi sözleşmeli araştırma ve peptit bazlı ilaç keşfine odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
GUBRA Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gubra A/S Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | DKK 391.80 |
| 52 Haftanın En Yüksek Seviyesi | DKK 557.50 |
| 52 Haftanın En Düşük Seviyesi | DKK 293.00 |
| Beta | 0.32 |
| 1 Aylık Değişim | 10.80% |
| 3 Aylık Değişim | 15.24% |
| 1 Yıllık Değişim | 5.04% |
| 3 Yıllık Değişim | 261.17% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | 256.18% |
Son Haberler & Güncellemeler
Analiz Makalesi • 19h
Earnings Beat: Gubra A/S (CPH:GUBRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Gubra A/S ( CPH:GUBRA ) missed earnings with its latest half-yearly results, disappointing overly-optimistic...
Anlatı Güncellemesi • Aug 21
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.
Yeni Anlatı • Aug 21
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?Recent updates
Analiz Makalesi • 19h
Earnings Beat: Gubra A/S (CPH:GUBRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Gubra A/S ( CPH:GUBRA ) missed earnings with its latest half-yearly results, disappointing overly-optimistic...Anlatı Güncellemesi • Aug 21
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.Yeni Anlatı • Aug 21
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Jun 24
GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.Anlatı Güncellemesi • Jun 10
GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.Anlatı Güncellemesi • May 26
GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Analiz Makalesi • May 14
Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...Anlatı Güncellemesi • Apr 27
GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).Anlatı Güncellemesi • Apr 12
GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).Anlatı Güncellemesi • Mar 29
GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential
Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).Anlatı Güncellemesi • Mar 15
GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.Anlatı Güncellemesi • Mar 01
GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).Anlatı Güncellemesi • Aug 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.Analiz Makalesi • Jun 28
Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Gubra A/S ( CPH:GUBRA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...Yeni Anlatı • May 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.Analiz Makalesi • May 04
We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analiz Makalesi • Mar 11
Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Gubra A/S ( CPH:GUBRA ) shareholders that were waiting for something to happen have been dealt a blow with a 26% share...Analiz Makalesi • Jan 14
We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analiz Makalesi • Jun 19
Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Gubra A/S ( CPH:GUBRA ) shareholders would be excited to see that the share price has had a great month, posting a 25...Analiz Makalesi • Mar 07
Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Despite an already strong run, Gubra A/S ( CPH:GUBRA ) shares have been powering on, with a gain of 60% in the last...Hissedar Getirileri
| GUBRA | DK Life Sciences | DK Pazar | |
|---|---|---|---|
| 7D | 5.4% | 4.5% | 0.7% |
| 1Y | 5.0% | 5.8% | -1.5% |
Getiri vs. Endüstri: GUBRA geçen yıl boyunca % 5.8 oranında getiri sağlayan Danish Life Sciences sektörüyle eşleşti.
Getiri vs Piyasa: GUBRA geçen yıl % -1.5 oranında getiri sağlayan Danish Piyasasını aştı.
Fiyat Oynaklığı
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 6.6% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 7.5% |
| 10% least volatile stocks in DK Market | 2.5% |
İstikrarlı Hisse Senedi Fiyatı: GUBRA hisse senedi fiyatı, son 3 ayda Danish piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: GUBRA 'nin haftalık oynaklığı ( 7% ) geçen yıl boyunca sabit kaldı, ancak hala Danish hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2008 | 330 | Markus Rohrwild | www.gubra.dk |
Bir biyoteknoloji şirketi olan Gubra A/S, Avrupa, Kuzey Amerika ve uluslararası alanda metabolik ve fibrotik hastalıklarda klinik öncesi sözleşmeli araştırma ve peptit bazlı ilaç keşfine odaklanmaktadır. Şirket üç segmentte faaliyet göstermektedir: Klinik Öncesi Sözleşmeli Araştırma (CRO), Keşif ve Ortaklıklar ve Gubra Green. İlaç ve biyoteknoloji endüstrisi için metabolik ve fibrotik hastalıklarda klinik öncesi sözleşmeli araştırma ve geliştirme hizmetleri sunmanın yanı sıra in vivo farmakoloji, biyobelirteç testleri, biyoinformatik, yeni nesil dizileme, farmakokinetik ve yapay zeka patolojisi ile 2D ve 3D histoloji hizmetleri sunmaktadır.
Gubra A/S Temel Bilgiler Özeti
| GUBRA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | DKK 6.43b |
| Kazançlar(TTM) | -DKK 182.25m |
| Gelir(TTM) | DKK 271.02m |
23.7x
P/S Oranı-35.3x
F/K OranıGUBRA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| GUBRA gelir tablosu (TTM) | |
|---|---|
| Gelir | DKK 271.02m |
| Gelir Maliyeti | DKK 66.97m |
| Brüt Kâr | DKK 204.05m |
| Diğer Giderler | DKK 386.30m |
| Kazançlar | -DKK 182.25m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
Mar 03, 2027
| Hisse başına kazanç (EPS) | -11.10 |
| Brüt Marj | 75.29% |
| Net Kâr Marjı | -67.25% |
| Borç/Özkaynak Oranı | 0% |
GUBRA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/23 01:41 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Gubra A/S 3 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |